Compare Progressive Corp (PGR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Progressive Corp trades at $218.73 (market cap $124.28B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Progressive Corp and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Progressive Corp pays a 0.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PGR | VRTX | |
|---|---|---|
Market Cap | $124.28B | $128.16B |
Volume | 2,551,191 | 806,603 |
Sector | Financials | Health |
52-Week High | $242.16 | $557.96 |
52-Week Low | $190.40 | $407.37 |
Typical Hold Time | 81 Days | 120 Days |
Enterprise Value | $132.48B | $122.29B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
